[Hyperthermic chemotherapy for peritoneal primary and gastrointestinal carcinomatoses].
Peritoneal carcinomatosis should no longer be considered as an automatically terminal disease in abdominal cancer patients. The aim of this comprehensive review of the literature was to evaluate the indications and contraindications of intraperitoneal hyperthermic chemotherapy with extensive cytoreduction surgery. Several aspects of the procedure are detailed. Feasibility, short-term and survival results are analysed owing to a comprehensive review of published studies.
Slim
K
K
Service de chirurgie générale et digestive, Hôtel-Dieu, boulevard Léon-Malfreyt, 63058, Clermont-Ferrand, cedex 1, France. kslim@chu-clermontferrand.fr
Glehen
O
O
Gilly
F N
FN
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D000075202:Contraindications; D005240:Feasibility Studies; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects / Q000379:methods*; D009017:Morbidity; D009367:Neoplasm Staging; D018579:Patient Selection; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D016016:Proportional Hazards Models; D024162:Second-Look Surgery; D016019:Survival Analysis; D016896:Treatment Outcome